BIOGNOSYS
21.10.2021 16:02:05 CEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars . In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”
Discovering biomarkers in cancer with next-generation plasma proteomics
The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.
Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing
at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”
Gaining insights on the immune system to support personalized drug development
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.
Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™
Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”
Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 14:00:00 CEST | Press release
Agreement to design, build and operate advanced water solution Project to advance integrated water reuse capability, significantly reducing freshwater demand Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the str
Seequent and Cascade Institute Partner to Map Canada’s Deep Geothermal Resources8.6.2026 14:00:00 CEST | Press release
State-of-the-art thermal model will provide a nationwide view of subsurface heat to accelerate Canada’s clean energy goals Seequent, The Bentley Subsurface Company, and the Cascade Institute today announced a collaboration to develop a Canadian Thermal Model. This landmark national initiative will reveal Canada’s deep geothermal resources and accelerate the development of renewable energy. The announcement comes on the opening day of the world’s biggest geothermal event, the World Geothermal Congress, being held in Calgary from 8 to 11 June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608741816/en/ The Canadian Thermal Model will integrate over 20 input layers of geoscientific data related to geothermal energy to evaluate Canada’s nationwide deep heat resources. As investment in geothermal energy surges globally as a reliable, always-on clean power source, the Canadian Thermal Model will create a comprehensive national
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform8.6.2026 14:00:00 CEST | Press release
Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief Scientific Officer, further building AdvanCell’s U.S. based leadership team Simon Puttick, PhD, transitions to Chief Isotope Development Officer and continues to lead isotope innovation efforts from Australia Appointments reflect AdvanCell’s continued investment in pipeline advancement, global scale-up, manufacturing readiness and isotope capabilities AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Justyna Kelly as Chief Technology Officer (CTO) and François Gaudet as Chief Scientific Officer (CSO), expanding the company’s executive leadership team in the U.S. as it continues to scale its U.S. capabilities, and advance its growing pipeline of innovative targeted alpha therapies. Justyna Kelly will lead AdvanCell’s global technical operations strategy, including CMC, GMP production and clinica
SLB OneSubsea Secures Subsea Boosting Contract for bp’s Thunder Horse Project in Gulf of America8.6.2026 14:00:00 CEST | Press release
Standardized system solution supports efficiency gains and shorter delivery timelines Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by bp to provide a subsea boosting system for the Thunder Horse project, a development in the deepwater portion of Gulf of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605895157/en/ SLB OneSubsea™ joint venture has been awarded a contract by bp to provide a subsea boosting system for the Thunder Horse project, a development in the deepwater portion of Gulf of America. This engineering, procurement and construction (EPC) contract for Thunder Horse follows recent subsea boosting contract awards for bp’s Kaskida and Tiber developments. All three projects leverage the same supplier-led, standardized subsea boosting system solution, which helps improve execution efficiency and shorten delivery times. As par
AB InBev Turns Bars into Stadiums During Biggest-Ever FIFA World Cup™8.6.2026 14:00:00 CEST | Press release
‘Cheers to Bars’ Global Platform Calls for People to Gather and Celebrate at Bars Everywhere Today, AB InBev, the world’s leading brewer, launched its global “Cheers to Bars” platform – a celebration of local bars and their impact on communities all over the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608956519/en/ Bars have always been more than places to grab a beer. They are where people come together to connect, celebrate milestones, build friendships, and create lasting memories. As hubs of social connection, bars play an important role in strengthening communities and bringing people closer together. “During the FIFA World Cup 2026™, bars will become the beating heart of every neighborhood – places where strangers become friends, every goal is celebrated as one, and collective memories are created with every raised glass,” said Michel Doukeris, CEO, AB InBev. “Beer and football have long been catalysts for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom